US Patent 9453222 Ligand-conjugated monomers
Patent 9453222 was granted and assigned to Alnylam Pharmaceuticals on September, 2016 by the United States Patent and Trademark Office.
All edits
Edits on 30 Jan, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 5 Dec, 2023
Golden AI
Edits made to:
Article (+158 characters)
Article
Patent abstract
This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.
Edits on 29 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Kallanthottathil G. Rajeev0
Muthiah Manoharan0
Venkitasamy Kesavan0
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09453222 Ligand-conjugated monomers US Patent 9453222 Ligand-conjugated monomers
Infobox
Patent Number
094532220
Patent Number
94532220
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
094532220
Date of Patent
September 27, 2016
0Patent Application Number
145822840
Date Filed
December 24, 2014
0Official Website
Patent Primary Examiner
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 8 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09453222 Ligand-conjugated monomers
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09453222
Date of patent
September 27, 2016
Patent application number
14582284
Date Filed
December 24, 2014
Patent primary examiner
Find more entities like US Patent 9453222 Ligand-conjugated monomers
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
